Streetbeat News

Stock Prices

FDX

FedEx shares are trading higher after the company reported better-than-expected Q4 financial results and issued guidance. Additionally, FedEx announced a $2.5 billion share buyback plan for FY25.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2024 | 11:29 am

SFLO

VSTO

Vista Outdoor Inc. (NYSE:VSTO) shares are trading higher premarket after MNC Capital Partners increased its all-cash offer to acquire Vista Outdoor to $42.00 per share, representing a significant premium. The revised proposal offers a 25% premium over the previous day's closing price and a 55% premium to the VWAP from October 16, 2023. MNC expects a merger agreement to be signed soon.

Portfolio Pulse from Nabaparna Bhattacharya

June 26, 2024 | 11:28 am

DAKT

Daktronics (NASDAQ:DAKT) reported Q4 earnings per share of $0.05, missing the analyst estimate of $0.15 by 66.67%. However, the company reported sales of $215.88 million, beating the estimate of $186.19 million by 15.95%. Compared to the same period last year, EPS decreased by 89.36% while sales increased by 2.87%.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2024 | 11:25 am

BTCUSD

Julian Assange, founder of WikiLeaks, is set to return to Australia after a long legal battle with the U.S. government. WikiLeaks turned to Bitcoin for financial support after being cut off by PayPal, Visa, and MasterCard. Bitcoin donations have significantly appreciated in value over the years.

Portfolio Pulse from Aniket Verma

June 26, 2024 | 11:21 am

AM

DHT

VTS

Wall Street's most accurate analysts have provided their ratings on three high-yielding energy stocks: DHT Holdings, Vitesse Energy, and Antero Midstream. These stocks offer dividend yields of over 6%, making them attractive to investors seeking stable returns. Analysts have given mixed ratings, with some upgrades and price target adjustments based on recent performance and market conditions.

Portfolio Pulse from Avi Kapoor

June 26, 2024 | 11:20 am

LYEL

Lyell Immunopharma announced promising initial clinical and translational data from its Phase 1 trial of LYL797, a reprogrammed ROR1 CAR T-cell product for blood cancers. The trial showed dose-dependent antitumor activity in ROR1+ relapsed/refractory triple-negative breast cancer, with a 40% objective response rate and 60% clinical benefit rate at the highest dose. No significant safety issues were observed, and development is expanding into new tumor types. An IND submission for LYL119, a next-generation ROR1-targeted CAR T cell product, has been completed.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2024 | 11:10 am

MGIH

Millennium Group Intl (NASDAQ:MGIH) reported a significant decline in its financial performance for the first half of the year, with an EPS of $(0.08) compared to $0.10 YoY and sales of $23.81M down from $26.33M YoY.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2024 | 11:06 am

GIS

General Mills expects its FY25 adjusted EPS to be between -1% and 1% in constant currency, compared to $4.52 in FY24.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2024 | 11:04 am

TLSA

Tiziana Life Sciences announced that it will dose the first patient with moderate Alzheimer's disease with its drug Foralumab.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2024 | 11:04 am

GIS

General Mills has projected its organic net sales growth for the fiscal year 2025 to be flat to +1%.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2024 | 11:03 am